Duties and liabilities of company directors.Legal uncertainty over EU market access of Swiss medical devices.Lower maximum prices of medicines as of April 2020.Right of access to documents in marketing authorisation applications confirmed.The Bolar and related exemptions in Europe: What activity do they cover?.Personal protective equipment COVID-19 export restrictions.NHS can procure drugs for use outside of their approved indications if it's cheaper, court says.COVID-19 and public compulsory licensing of drugs in Europe.Privacy regulator guidance for life sciences and healthcare in light of COVID-19.Patents diary June 2020: UK Supreme Court holds Regeneron's transgenic mice patents invalid.Legal advice privilege: where are we now?.

Arbitration for life sciences companies.Too sweet to throw away? Sweetened/carbonated beverages industry law changes in Poland.Territorial licensing: 'start at the end before you begin'.Patent diary – July 2020: Court refuses to strike out Chiesi's quia timet injunction claim.Private equity investment in life sciences sector.Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents.UK increases scrutiny of tech and life sciences deals.IP, divestments, fragmentation and the future: M&A in life sciences.Arbitration: considerations for life science companies.The 2020s: Boris Johnson's decade to prove his life sciences plan.Taking security over IP: counting the cost.National perspectives on the CJEU Bayer decision.Competition law and coronavirus: what’s the connection?.SPC manufacturing waiver (Part 3): Notification obligations – Information is power.

Parts of a document